Æó¾ÏÀÇ Á¤À§ÀûüºÎ¹æ»ç¼±Ä¡·á½Ã È£Èí ¿òÁ÷ÀÓ¿¡ µû¸¥ 3D ¼±·® ÃøÁ¤Æò°¡
A study to 3D dose measurement and evaluation for Respiratory Motion in Lung Cancer Stereotactic Body Radiotherapy Treatment

´ëÇѹæ»ç¼±Ä¡·áÇÐȸÁö 2014³â 26±Ç 1È£ p.59 ~ p.67

ÃÖº´°É() - Áß¾Óº¸Èƺ´¿ø ¹æ»ç¼±Á¾¾çÇаú
ÃÖâÇå() - Áß¾Óº¸Èƺ´¿ø ¹æ»ç¼±Á¾¾çÇаú
À±ÀϱÔ() - Áß¾Óº¸Èƺ´¿ø ¹æ»ç¼±Á¾¾çÇаú
¾çÁø¼º() - Áß¾Óº¸Èƺ´¿ø ¹æ»ç¼±Á¾¾çÇаú
À̵¿¸í() - Áß¾Óº¸Èƺ´¿ø ¹æ»ç¼±Á¾¾çÇаú
¹ÚÁÖ¹Ì() - Áß¾Óº¸Èƺ´¿ø ¹æ»ç¼±Á¾¾çÇаú

Abstract

¸ñ Àû : Æó¾ÏÀÇ Á¤À§ÀûüºÎ¹æ»ç¼±Ä¡·á½Ã ½ÇÁ¦ Àû¿ëÇÏ°í ÀÖ´Â ÃÖ´ë°­µµÅõ»ç(MIP) ¿µ»ó°ú È£ÈíÀ§»óº°(0¡­90%)¿µ»ó¿¡¼­ 3Â÷¿øÀûÀ¸·Î À籸¼ºµÈ ¼±·® ºÐÆ÷ Â÷À̸¦ Æò°¡ÇÏ°íÀÚ ÇÑ´Ù.

´ë»ó ¹× ¹æ¹ý : º»¿ø¿¡¼­ Á¤À§ÀûüºÎ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÑ ºñ¼Ò¼¼Æ÷¼º Æó¾Ï(NSCLC) ȯÀÚ 5¸íÀ» ´ë»óÀ¸·Î 4Â÷¿ø Àü»êÈ­´ÜÃþ¿µ»óÀ» ½ÃÇàÇÏ¿© 10°³ÀÇ È£ÈíÀ§»óº° ¿µ»óÀ» ȹµæÇÑ ÈÄ ÃÖ´ë°­µµÅõ»ç ¿µ»óÀ» À籸¼ºÇÏ¿© °¢ È£ÈíÀ§»óº° Ä¡·á°èȹÀ» ¼ö¸³ÇÏ¿´°í, 2Â÷¿ø ÀÌ¿ÂÀü¸®ÇÔ°ú ¼±·®ºÐ¼®ÇÁ·Î±×·¥ COMPASS(IBA dosimetry, Schwarzenbruck, Germany)À» ÀÌ¿ëÇÏ¿© 3Â÷¿øÀûÀ¸·Î À籸¼ºµÈ ¼±·®ºÐÆ÷¸¦ ÃøÁ¤ÇÏ¿´´Ù. À̸¦ ÀÌ¿ëÇÏ¿© Ä¡·á°èȹ ¼±·®ºÐÆ÷¿Í ½ÇÁ¦ ÃøÁ¤ ¼±·®ºÐÆ÷ÀÇ ÀÏÄ¡¼º ¿©ºÎ ¹× ÃÖ´ë°­µµÅõ»ç ¿µ»ó°ú È£ÈíÀ§»óº° ¿µ»ó¿¡¼­ ¼±·® ºÐÆ÷ÀÇ Â÷À̸¦ Á¤·®ÀûÀ¸·Î ºñ±³ ºÐ¼®ÇÏ¿´´Ù.

°á °ú : ÃÖ´ë°­µµÅõ»ç ¿µ»ó ¹× È£ÈíÀ§»óº° ¿µ»ó¿¡¼­ÀÇ ¼±·®ºÐÆ÷ÀÇ ÀÏÄ¡¼ºÀ» ¾Ë¾Æº¸±â À§ÇÑ °¨¸¶ºÐ¼® Åë°úÀ²Àº ´ë»ó ȯÀÚ ¸ðµÎ 99%ÀÌ»óÀ¸·Î Æò°¡±âÁØÀ» ¸¸Á· ½ÃÄ×À¸¸ç, °¢°¢ÀÇ È¯Àڵ鿡 ´ëÇÑ ÃÖ´ë°­µµÅõ»ç ¿µ»ó°ú È£ÈíÀ§»óº° ¿µ»ó¿¡¼­ À籸¼ºµÈ ¼±·®ÀÇ HI(Homogeneity Index) Â÷ÀÌÀÇ Æò±ÕÀº -0.03¡­0.04·Î Å©Áö ¾Ê¾ÒÀ¸¸ç, PTV(Planning Target Volume)ÀÇ Dmax Â÷ÀÌ´Â Æò±Õ 3.30 cGy, ô¼ö´Â Æò±Õ 40 cGy, ¾çÃø Æó, ¿ìÆó, ÁÂÆóÀÇ V20, V10, V5 Â÷ÀÌ´Â Æò±Õ -0.04¡­2.32% Â÷À̸¦ ³ªÅ¸³»¾ú´Ù. ¶ÇÇÑ ¸ðµç ȯÀÚ¿¡ ´ëÇÑ ÃÖ´ë°­µµÅõ»ç ¿µ»ó°ú È£ÈíÀ§»óº° ¿µ»ó¿¡¼­ À籸¼ºµÈ ¼±·®ÀÇ HI Â÷ÀÌÀÇ Æò±ÕÀº -0.03¡­0.03·Î Å©Áö ¾Ê¾ÒÀ¸¸ç, PTVÀÇ Dmax Â÷ÀÌÀÇ Æò±ÕÀº 10% ¿µ»ó¿¡¼­ °¡Àå Â÷ÀÌ°¡ ÀÛ¾Ò°í, 70% ¿µ»ó¿¡¼­ °¡Àå Å« Â÷À̸¦ ³ªÅ¸³»¾ú´Ù. ô¼öÀÇ DmaxÂ÷ÀÌÀÇ Æò±ÕÀº 50% ¿µ»ó¿¡¼­ °¡Àå Â÷ÀÌ°¡ ÀÛ¾Ò°í, 0% ¿µ»ó¿¡¼­ °¡Àå Å« Â÷À̸¦ ³ªÅ¸³»¾ú´Ù. Æó V20, V10, V5ÀÇ Â÷ÀÌÀÇ Æò±ÕÀº È£ÈíÀ§»óº°·Î ÀÏÁ¤ÇÑ °æÇ⼺À» ³ªÅ¸³»Áö ¾Ê¾Ò´Ù.

°á ·Ð : º» ¿¬±¸¸¦ ÅëÇØ ÃÖ´ë°­µµÅõ»ç ¿µ»ó°ú °¢ È£ÈíÀ§»óº° ¿µ»ó¿¡¼­ ÃøÁ¤µÇ¾î 3Â÷¿øÀûÀ¸·Î À籸¼ºµÈ ¼±·®ºÐÆ÷Â÷ÀÌ´Â ÀÏÁ¤ÇÑ °æÇâÀ» ³ªÅ¸³»Áö´Â ¾Ê¾ÒÁö¸¸ ƯÁ¤ È£ÈíÀ§»ó¿¡¼­ ¼±·® ºÐÆ÷ Â÷ÀÌ°¡ »óÀÌÇÑ °æ¿ì¸¦ º¼ ¼ö ÀÖ¾ú´Ù. Á¾¾çÀÇ À§Ä¡ ¹× È£Èí ¿òÁ÷ÀÓÀÌ À¯»çÇÑ ´ë»óȯÀÚ±ºÀ» ¼±Á¤ÇÏ¿© ü°èÀûÀÎ ¿¬±¸¸¦ ÅëÇØ µ¥ÀÌÅÍÈ­ ÇÏ°Ô µÇ¸é Æó¿Í °°ÀÌ ¿òÁ÷ÀÓÀÌ Å« Àå±âÀÇ Á¤À§ÀûüºÎ¹æ»ç¼±Ä¡·á½Ã ƯÁ¤ È£ÈíÀ§»ó¿¡¼­ ȹµæÇÑ ¿µ»ó¿¡¼­ÀÇ Ä¡·á°èȹÀÌ ½ÇÁ¦ Ä¡·á¿¡ Àû¿ëµÇ¾î¾ß ÇÏ´ÂÁö¿¡ ´ëÇÑ ÀûÇÕ¼º ¿©ºÎ¸¦ ÆÇ´Ü ÇÒ ¼ö ÀÖÀ» °ÍÀ̶ó°í »ç·áµÈ´Ù.
Purpose : This study aims to evaluate 3D dosimetric impact for MIP image and each phase image in stereotactic body
radiotherapy (SBRT) for lung cancer using volumetric modulated arc therapy (VMAT).

Materials and Methods : For each of 5 patients with non-small-cell pulmonary tumors, a respiration-correlated fourdimensional computed tomography (4DCT) study was performed . We obtain ten 3D CT images corresponding to phases of a breathing cycle. Treatment plans were generated using MIP CT image and each phases 3D CT. We performed the dose verification of the TPS with use of the Ion chamber and COMPASS. The dose distribution that were 3D reconstructed using MIP CT image compared with dose distribution on the corresponding phase of the 4D CT data.

Results : Gamma evaluation was performed to evaluate the accuracy of dose delivery for MIP CT data and 4D CT data of 5
patients. The average percentage of points passing the gamma criteria of 2 mm/2% about 99%. The average Homogeneity
Index difference between MIP and each 3D data of patient dose was 0.03¡­0.04. The average difference between PTV
maximum dose was 3.30 cGy, The average different Spinal Coad dose was 3.30 cGy, The average of difference with V20, V10, V5 of Lung was -0.04%¡­2.32%. The average Homogeneity Index difference between MIP and each phase 3d data of all patient was -0.03¡­0.03. The average PTV maximum dose difference was minimum for 10% phase and maximum for 70% phase. The average Spain cord maximum dose difference was minimum for 0% phase and maximum for 50% phase. The average difference of V20, V10, V5 of Lung show bo certain trend.

Conclusion : There is no tendency of dose difference between MIP with 3D CT data of each phase. But there are ppreciable difference for specific phase. It is need to study about patient group which has similar tumor location and breathing motion. Then we compare with dose distribution for each phase 3D image data or MIP image data. we will determine appropriate image data for treatment plan.

Å°¿öµå

Á¤À§ÀûüºÎ¹æ»ç¼±Ä¡·á, ÃÖ´ë°­µµÅõ»ç¿µ»ó, È£ÈíÀ§»ó
Stereotactic body radiotherapy(SBRT), MIP image, respiratory motion
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
The average percentage of points passing the gamma criteria of 2 mm/2% about 99%. The average Homogeneity Index difference between MIP and each 3D data of patient dose was 0.03¡­0.04. The average difference between PTV maximum dose was 3.30 cGy.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå